Boundless Bio

IPO

Unlocking a New Paradigm in Cancer Therapeutics

San Diego, United States · Founded 2018 · $251.4M raised

Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$251.4M
Last Round
$100.0M Series CMay 2023
Rounds
3

About

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in over 17% of cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality and develops small molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit cancer cell growth and resistance.

Summary

Boundless Bio is a Biotech company based in San Diego, United States, founded in 2018. It has raised $251.4M in total across 3 rounds, most recently a $100.0M Series C round in May 2023. Investors include Leaps by Bayer, RA Capital Management and Alexandria Venture Investments.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

IPOMar 2024
$100.0M

Sign up to see all 4 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Boundless Bio on Indexed.vc
<a href="https://indexed.vc/companies/boundless-bio"><img src="https://indexed.vc/api/badge/company/boundless-bio" alt="Boundless Bio on Indexed.vc" width="260" height="76" /></a>